



Translational research on pancreatic β -cells for the treatment of diabetes

Jun Shirakawa, MD, PhD

Professor, Laboratory of Diabetes and Metabolic
Disorders, Institute for Molecular and Cellular
Regulation (IMCR), Gunma University

令和5年8月25日(金) 16:00–18:00
健康医科学イノベーション棟105室

Abstract

The decline in β -cell mass due to the failure of β -cell compensation or the β -cell death is one cause of the development of both type 1 and type 2 diabetes. Therefore, elucidation of the mechanism by which an adaptive increase in β -cell mass through interorgan networks occurs in vivo will lead to the development of a cure for diabetes. The immune system is an emerging target as an important player in regulating β -cell function and mass. A remaining barrier for the treatment of human diabetes using β -cells is the differences between human and rodent islets. In this seminar, I will focus on the crosstalks between islets and other tissues that regulate adaptive β -cell proliferation for the treatment of diabetes considering the abovementioned issues.

問合せ先：免疫学・澁谷 彰 (ashibuya@md.tsukuba.ac.jp)
TEL: 029-853-3281

共催：ヒューマンバイオロジー学位プログラム
：ヒューマニクス学位プログラム
：医学学位プログラム
：フロンティア医科学学位プログラム